Specialist pharmaceutical and medical technologies business, LINK Healthcare (‘LINK’), reports that one of its products, Colistin-Link, is gaining stature in the treatment of multi drug resistant bacteria. Today, infectious disease kills more people than cancer and so called “superbugs”, bacteria that don’t respond to antibiotics, are emerging as a major health threat. In a recent

Gentium To Initiate Clinical Development in Japan and Expand Named-Patient Program Access to Asia and Japan VILLA GUARDIA (COMO), Italy, December 5, 2012 (GlobeNewswire) – Gentium S.p.A. (NASDAQ: GENT) (the “Company”) today announced the Company’s entry into an agreement with the National University Corporation Hamamatsu University School of Medicine (“HUSM”), Fukushima Medical University (“FMU”) and